Patents
US 12747234 B2: Kinase inhibitors for the treatment of neurodegenerative diseases
- Granted
- 2026-09-29
- Filed
- 2021-10-12 application 18249147
- Type
- Utility · 19 claims
- Elsewhere
- Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗
Abstract
Described herein are compounds that are kinase inhibitors. The disclosed compounds have improved properties that lead to specific targeting of kinases without inhibiting the activity of related enzymes including, making them useful for therapeutic intervention in a variety of disorders and disease in which inhibition of the kinase can be clinically useful, e.g., Alzheimer's disease and other neurodegenerative diseases. In further aspects, the disclosed compounds can be used in methods of treating a neurodegenerative disease associated with inflammation, such as Alzheimer's disease, Huntington's disease, Parkinson's disease, epilepsy, stroke, amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), or a disease or disorder such as deafness, glaucoma, organ failure, or cancers, including, but not limited to, those susceptible to combination therapy with epigenetic targets such as those associated with bromodomain (BRD) proteins, histone deacetylases (HDACs), and the like.
Source: PTBLXML, file of 2026-09-29 (ipgb20260929.xml).
Assignees
| Assignee | Type | Place | Also on furp.org | Source |
|---|---|---|---|---|
| Ohio State Innovation Foundation 733 patents | US company or organization | Columbus, OH | OHIO STATE INNOVATION FOUNDATION Nonprofit EXACT high confidence: identical full name and state | PTBLXML, file of 2026-09-29 |
| REACTION BIOLOGY CORPORATION 6 patents | US company or organization | Malvern, PA | PTBLXML, file of 2026-09-29 |
Inventors
| Inventor | Place | Patents | Person page | Source |
|---|---|---|---|---|
| Yangbo Feng | Malvern, PA | 6 | PTBLXML, file of 2026-09-29 | |
| Sung Ok Yoon | Columbus, OH | 2 | PTBLXML, file of 2026-09-29 |
CPC categories
| Subclass | Category | First group | Source |
|---|---|---|---|
| C07D | Heterocyclic compounds | C07D409/14 | PTBLXML, file of 2026-09-29 |
| A61K | Preparations for medical, dental or toiletry purposes | A61K31/4155 | PTBLXML, file of 2026-09-29 |
Cooperative Patent Classification, as currently assigned (one row per subclass).
Assignments and security interests
| Recorded | What | From | To | Reel/frame | Source |
|---|---|---|---|---|---|
| 2026-04-03 | Assignment Assignment of assignor's interest | FENG, YANGBO signed 2023-10-24 | REACTION BIOLOGY COPORATION MALVERN, PA | 75338/588 | PASDL, file of 2026-09-24 |
Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.
USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.